Conatus Starts Phase II Trial for Hepatitis Treatment
Posted on: Friday, 21 December 2007, 12:00 CST
Conatus Pharmaceuticals has initiated a Phase II clinical trial with CTS-1027, a novel drug candidate for the treatment of liver disease associated with hepatitis C virus infection in patients who have failed the approved standard-of-care treatments.
The clinical trial is a double-blind, placebo-controlled, multiple-dose trial lasting for four weeks followed by a voluntary open label period of up to eight additional weeks. The company expects approximately 100 patients to be enrolled. The clinical trial will be conducted at up to ten medical centers in the US.
The oral, small molecule drug candidate, CTS-1027, is being studied as a treatment for the inflammatory damage to the liver resulting from infection by HCV. CTS-1027 inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases. CTS-1027 has been shown to be effective in multiple preclinical models of liver disease.
Steven Mento, president and CEO of Conatus, said: "We believe that CTS-1027 represents a novel approach to treating liver inflammation and look forward to developing this drug candidate to fill an important medical need in HCV-infected patients."
Source: Datamonitor
Related Articles
- GlycoMimetics, Inc. Commences Phase 1 Clinical Trial of Lead Drug Candidate
- Insert Therapeutics to Initiate a Multinational Phase II Clinical Trial of Lead Drug Candidate IT-101 in Ovarian Cancer
- Sirtris Pharmaceuticals Enters Collaborative Study Testing New Chemical Entities and Clinical Drug Candidate In Multiple Models of Cancer With the National Cancer Institute
- Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
- Gene Logic and Solvay Pharmaceuticals Enter Agreement to Discover New Development Paths for Multiple Clinical Drug Candidates
- Diffusion Pharmaceuticals Initiates Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC)
- Gene Logic and Roche Enter Collaboration to Discover New Development Paths for Multiple Clinical Drug Candidates
- Chiron and XOMA Announce Initiation of Phase I Clinical Trial for CHIR-12.12 in Multiple Myeloma -- Second Clinical Trial Evaluating Oncology Drug Candidate Begins
- Rockville-Based EntreMed Inc. Obtains Two New Patents for Its Lead Clinical Drug Candidate
- Corgentech Initiates Enrollment in Additional Phase 1/2 Trial of New Drug Candidate for Eczema
 |
 |
User Comments (0)
RSS Feeds